SCHEMBL21538079

SCHEMBL21538079

CC(=O)N1CCN(C(=O)c2cc([S+]([O-])Nc3ccc(S(C)(=O)=O)cc3)ccc2Cl)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.69
ALDH1A1 P00352 2/20 0.55
LMNA P02545 4/20 0.41
HSP90AA1 P07900 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NR1I2 O75469 1/20 0.39
CACNA1B Q00975 1/20 0.39
GPR55 Q9Y2T6 2/20 0.39
CNR1 P21554 1/20 0.39
AVPR2 P30518 1/20 0.38
GPR27 Q9NS67 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24750094 0.88 NPC1 (0.53) NPC1ALDH1A1LMNAHSP90AA1TP53
SCHEMBL12332 0.82 NPC1 (1.00) NPC1ALDH1A1LMNATP53GAA
SCHEMBL14198866 0.72 LMNA (0.68) NPC1ALDH1A1LMNAHSP90AA1TP53
SCHEMBL7605183 0.71 ALDH1A1 (1.00) NPC1ALDH1A1LMNAABL1RIN1
SCHEMBL12106 0.70 NPC1 (0.73) NPC1ALDH1A1LMNATP53
SCHEMBL4930270 0.68 SMN1; SMN2 (0.59) NPC1ALDH1A1LMNAALOX15TSHR
SCHEMBL21538162 0.67 ALDH1A1 (0.50) ALDH1A1LMNAHSP90AA1TSHRMEN1
SCHEMBL18516792 0.67 NPC1 (0.69) NPC1ALDH1A1LMNAMEN1KMT2A
SCHEMBL20976539 0.65 ALDH1A1 (0.42) ALDH1A1LMNATSHRMEN1KMT2A
SCHEMBL15567733 0.65 GPR6 (0.54) NPC1ALDH1A1LMNAABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3561077-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS Agios Pharmaceuticals, Inc. (US) 2019-10-30 EP disclosed